The impact ofFcγRIIaandFcγRIIIagene polymorphisms on responses to RCHOP chemotherapy in diffuse large B-cell lymphoma patients.
Rituximab is a monoclonal antibody routinely used in the treatment of B-cell non-Hodgkin lymphomas. It mediates antibody-dependent cellular cytotoxicity of B lymphocytes by bridging them with Fcγ receptors (FcγR) on effector cells. Several polymorphisms in theFcγRgenes have been identified to influence rituximab binding to FcγR, thus altering its antitumor effect in indolent lymphomas. In the present study, the impact ofFcγRIIaandFcγRIIIapolymorphisms on the survival and response to immunochemotherapy consisting of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone was evaluated in diffuse large B-cell lymphoma (DLBCL) patients. A total of 29 Slovenian DLBCL patients were studied. Genotyping was conducted forFcγRIIa-27,FcγRIIa-131,FcγRIIIa-48 andFcγRIIIa-158 polymorphisms. The median follow-up time was 29.7 months (range, 9.7-45.4 months). No significant impact of the genotypes was observed on the treatment response, progression-free or overall survival of DLBCL patients. There was a non-significant trend of an improved response to chemotherapy without additional irradiation in patients homozygous for Val atFCγIIIa-158 compared to Phe carriers. The findings of the present study indicate thatFcγRpolymorphisms have no influence on the survival of DLBCL patients.
Department of Pharmacy, Institute of Oncology Ljubljana, Ljubljana 1000, Slovenia.
Samo
S
Rožman
Department of Molecular Diagnostics, Institute of Oncology Ljubljana, Ljubljana 1000, Slovenia.
Srdjan
S
Novaković
Department of Biopharmaceutics and Pharmacokinetics, Faculty of Pharmacy, University of Ljubljana, Ljubljana 1000, Slovenia.
Iztok
I
Grabnar
Department of Molecular Diagnostics, Institute of Oncology Ljubljana, Ljubljana 1000, Slovenia.
Petra
P
Cerkovnik
Division of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana 1000, Slovenia.
Barbara Jezeršek
BJ
Novaković
Fcγ receptor; genetic polymorphism; lymphoma; rituximab